Last month, Jacques Livage delivered his first lecture for his chair in condensed matter chemistry at the Collège de France. It marked the first time since 1930 that two chemists have held such positions at the Collège de France. The other chemistry chair is held by Jean-Marie Lehn, who shared the chemistry Nobel prize in 1987.
Livage has been a professor of chemistry at the Pierre and Marie Curie University in Paris since 1973, but his new position means that he will no longer handle administrative duties there. Instead, he will continue with his lab research, and will prepare and deliver 18 lectures a year around the country. "We're not allowed to give the same lecture twice," Livage says. That challenge will allow him to present up-to-date scientific material to his audiences. "It's a very pleasant thing to give lectures on an interesting topic," he says, "and you have no exams."
The timeliness of his lecture subjects will help them to meld with his research interests in solid-state chemistryespecially chimie douce ('soft chemistry'), which he helped to pioneer with Jean Rouxel in the 1970s. Livage is keen on making hybrid materials by using soft-solution processing approaches to mix organic and inorganic starting materials. His lab is also working on trapping bacteria inside silica gels -an approach that he hopes will result in new types of biosensor and drug-delivery systems.
PHARMACEUTICALS
Jeffrey Nye paved the way for his transition from academia to industry through a steady stream of consulting work. Nye left the Northwestern University Medical School in Chicago late last year to take up a post with drug company Pharmacia in Kalamazoo, Michigan. But he has been advising drug-development companies and venture capitalists since he was a graduate student. While at Northwestern, Nye's work focused on the genetics of spina bifida.
As director of central nervous systemrelated genomics discovery for Pharmacia, Nye is enthusiastic about the potential of therapeutics for Alzheimer's disease. The chance to translate basic research on that disease into potential treatment was one attraction that lured him to the job. He also enjoys being involved in business, medicine, science and law. "Here I get to merge all my interests," he says of his new post. When he joined the JGI as deputy director in 1999, its funding and mission were unclear. But that all changed when the JGI played an important role in sequencing the human genome -an accomplishment that Hawkins found gratifying. "It's always nice to leave on a high," he says.
In some respects, his departure from the institute is a return to his commercial roots. Before joining the JGI, Hawkins was vice-president of genomics for CuraGen, a biotech company in New Haven, Connecticut. There he had an almost entirely scientific role. At Amersham, he is looking to branch out, taking on business development and marketing responsibilities. "I had always seen my future as running a commercial enterprise," he says. "This is a good step forward for my own career goals." 
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